TCF1+ CD8+ TILs predict response to therapy and were correlated to a positive outcome in patients. TCF7+ CD8+ T cells were enriched in tumor biopsies obtained from metastatic SKCM patients responding to ICB treatment. The gene discussed is TCF7; the disease is neoplasm.